Introduction {#Sec1}
============

Ageing is a complex process characterized by loss of tissue homeostasis and a progressive and widespread decline in physical performance and cognitive functions of the whole organism. Tissue integrity is physiologically maintained by resident stem cells, which are able to replace damaged or lost cells. Recent advances in stem cell research have proposed an intriguing hypothesis concerning ageing: exhaustion of stem cells may be a primary cause of ageing (Sharpless and DePinho [@CR28]; Sahin and Depinho [@CR26]). Adult stem cells can be found in tissues throughout the human body, including bone marrow and fat. These cells although pluripotent, contrary to embryonic stem cells, have a differentiation capability limited to the retention of tissue homeostasis, by replacing damaged or dying cells throughout the human life span (Bryder et al. [@CR6]; Morrison and Kimble [@CR19]). They exhibit specific physiological and biochemical properties. First of all, mesenchymal stem cells (MSCs) can differentiate into distinctive end-stage cell types, required to form many mesenchymal tissues, including bone, cartilage, muscle, bone marrow stroma, tendons/ligaments, fat, dermis, and other connective tissues. Moreover, MSCs participate to the injury response by a so-called "homing capacity," through which they can localize into the damaged tissue and secrete a wide range of bioactive molecules with "trophic activity" (Wright et al. [@CR32]). However, the regenerative capability of MSCs is subjected to a series of biochemical changes that occurs during ageing, and deeply affect their self-renewal potential. It seems that the expression of specific mediators of senescence, may act through tumor suppressing and growth arrest mechanisms, playing a very important role in aging. Among these, the cyclin-dependent kinase inhibitors, p16INK4a and ARF, significantly accumulates with normal aging in rodents and humans in cells of a variety of tissues (Alcorta et al. [@CR1]; Rheinwald et al. [@CR23]; Randle et al. [@CR22]; Chkhotua et al. [@CR9]; Melk et al. [@CR17]; Nielsen et al. [@CR20]; Zindy et al. [@CR34]). The activation of p16INK4a and ARF induces p53 pathways, including the expression of the cyclin-dependent kinase inhibitors p21^CIP1^, leading to cell cycle arrest and regenerative defects (Bringold and Serrano [@CR5]).

Moreover, during ageing, cells undergo senescence-associated changes which include cellular widening, higher lysosome biogenesis, and expression of a beta-galactosidase that has a pH optimum of 6 (senescence-associated β-galactosidase or SA-β-Gal). It is now generally accepted that stem cells, which undergo accelerated cellular senescence, can contribute to age-related diseases (Vijg and Campisi [@CR31]). We have previously shown that a treatment, named tissue optimization-regenerative (TO-RGN), of radio-electric asymmetric conveyer (REAC) technology (Rinaldi and Fontani [@CR24], [@CR25]), significantly influenced the differentiation capability of mouse embryonic stem cells (Maioli et al. [@CR13]), as well as pluripotency and plasticity of human skin-derived fibroblasts (Maioli et al. [@CR14]). In the present study, we investigated whether TO-RGN may be able to counteract the expression of SA-β-Gal and modulate the transcription of a number of senescence mediator genes, recruited throughout prolonged culturing of human, adipose-derived stem cells (hADSCs).

Material and methods {#Sec2}
====================

Ethics statement {#Sec3}
----------------

According to the policy approved by the local ethical committee of the University of Bologna (title of approved project: "Assessment of mesenchymal stem cells in human adipose tissue," code number 013/2010/O/Tess, date of approval from the ethical committee: 16 February 2010), all tissue samples were obtained after informed consent. All participants, according to the consent procedure approved by the ethical committee, provided their written consent specifically dedicated to the harvesting of their abdominal fat (50--100 mL of lipoaspirate).

Radio-electric asymmetric conveyer technology for therapeutic use {#Sec4}
-----------------------------------------------------------------

REAC is an innovative patented technology (WO2002004069) (Rinaldi and Fontani [@CR24], [@CR25]) for bio-stimulation and/or bio-enhancement techniques that induces weak radio-electric currents in the tissues, to induce a cell reprogramming activity (Maioli et al. [@CR14]). The model used in this study (B.E.N.E Bio enhancer--Neuro enhancer, ASMED, Florence, Italy) is specific for regenerative treatments. Recently, using TO-RGN treatment protocol, the REAC technology has demonstrated the chance to drive stem cell pluripotency and differentiation (Maioli et al. [@CR13]), and a cell reprogramming activity (Maioli et al. [@CR14]).

The physical underpinnings of REAC technology are the following: upon interaction of two oscillators, namely two electromagnetic fields, a resultant oscillatory pattern may be generated, in actual fact a resultant current and magnetic field. Exploitation of the REAC technology implies that among the interacting oscillators, one is represented by the oscillating electromagnetic field generated by cells or by the entire organism and the other by a weaker electromagnetic field produced by the REAC apparatus itself. Upon the establishment of such a dual system, a resultant electromagnetic field is generated that induces the cells or the organism to respond in an autologous fashion with self-generated radio-electric microcurrents, likely ensuing from an array of cellular ionic fluxes. By the aid of REAC technology, these autologous radio-electric currents can be asymmetrically focused with a conveyer probe to produce a therapeutic effect on a given selected area of the entire organism or elicit transcriptional and signaling events that drive reprogramming and differentiating decisions in isolated (stem) cell cultures. The unique features of the REAC technology thus provide a complete customization and non-invasiveness of treatments, in the absence of side effects, due to the nature of the treatment itself. On the whole, these achievements pave the way to novel perspectives at the level of both basic science and clinical settings that are currently approached according to specific validated protocols.

REAC tissue optimization: regenerative treatment (TO-RGN) {#Sec5}
---------------------------------------------------------

The REAC TO-RGN consists of a sequence of radio frequency burst of 250 ms with an off interval of 2.5 s. The REAC apparatus, was placed into a CO~2~ incubator, was set at a frequency of 2.4 GHz, and its conveyer electrodes were immersed into the culture medium of hADSCs. REAC radiated power is about 2 mW, electric field *E* = 0.4 V/m, Magnetic field 1 mA/m, specific absorption rate (SAR) 0.128 μW/g; the density of radio-electric current flowing in the culture medium during the REAC single radio frequency burst is *J* = 30 μA/cm^2^.

Isolation and culture of hADSCs {#Sec6}
-------------------------------

Human subcutaneous adipose tissue samples were obtained from lipoaspiration/liposuction procedures by 50-year-old female donors (*n* = 14). Their mean BMI was 25.47 and their mean age was 49.57. After washing, lipoaspirates were digested with 0.2 % collagenase A type I solution (Sigma-Aldrich), under gentle agitation for 45 min at 37 °C, and centrifuged at 2,000×*g* for 10 min to separate the stromal vascular fraction from adipocytes. If necessary, the hADSC fraction was treated with red blood cell lysis buffer for 5 min at 37 °C, and then centrifuged again. The supernatant was discarded, and the cell pellet was resuspended and seeded in culture flasks in DMEM-low glucose (Lonza) supplemented with 20 % heat inactivated FBS, 1 % penicillin-streptomycin, 2 mM L-glutamine, and incubated at 37 °C in a humidified atmosphere with 5 % CO~2~. When the cultures were near confluence, the cells were detached by treatment with trypsin and seeded in six-well tissue culture plates (3 × 10^3^ cells/cm^2^) at the appropriate passages. The REAC apparatus, was placed into a CO~2~ incubator, was set at 2.4 GHz, and its conveyer electrodes were immersed for 4, 8, or 12 h into the culture medium of hADSCs at passages 5, 10, 15, 20, 25, and 30. The widths and lengths of at least ten individual controls and TO-RGN-treated hADSCs at different passages were recorded using an Olympus IX71 fluorescence-inverted microscope at 100× magnification oil immersion. Images were analyzed with the software "ANALYSIS," and these data were averaged to produce a single average measurement of cell length and width.

Characterization of hADSCs by flow cytometry analysis {#Sec7}
-----------------------------------------------------

ADSCs obtained from adipose tissues were harvested by treatment with 0.08 % trypsin-EDTA and incubated with 1 μg/10^6^ cells FITC-conjugated antibodies for 40 min at 4 °C in the dark. The antibodies used were: SH2, SH3, SH4, anti-CD166, anti-CD14, anti-CD34, anti-CD44, and anti-CD45. After washing, cells were analyzed on a flow cytometer (FACSCalibur, Becton Dickinson, San Jose, CA, USA) by collecting 10,000 events and the data analyzed using the Cell Quest Software (Becton Dickinson). hADSCs were positively stained with SH2, which identifies an epitope of endoglin (CD105), were recognized by the SH3 and SH4 antibodies, which identify epitopes on culture-expanded stromal cells and bind CD73, a molecule involved in B cell activation. hADSCs were also positive for CD29, the beta-subunit of an integrin family behaving as the major receptor for extracellular matrix molecules, CD166, an hMSC marker not found in hematopoietic precursors, and were uniformly positive for the CD44 hyaluronate receptor. Conversely, antigen profiles were negative for the hematopoietic markers CD14 and CD34 and the leukocyte common antigen CD45.

Senescence associated β-galactosidase staining {#Sec8}
----------------------------------------------

SA-β-Gal staining was performed using a "Senescence-associated β-Galactosidase Staining Kit" (Cell Signalling). Briefly, hADSCs cultured at passages 5, 10, 15, 20, 25, and 30 were exposed for 12 h in the absence or presence of REAC in six-well plates (3 × 10^3^ cells per well). Subsequently, cells were fixed with fixative solution and then processed according to the manufacturer's instructions. All the experiments were repeated three times, and one of the representative results was shown. The cells were then photographed under an inverted microscope at 100× magnification for qualitative detection of SA-β-Gal activity. The number of positive (blue) and negative cells was counted in five random fields under the microscope (at 200× magnification and bright field illumination), and the percentage of SA-β-Gal-positive cells was calculated as the number of positive cells divided by the total number of counted cells.

Assessment of cell viability {#Sec9}
----------------------------

hADSCs cultured at passages 5, 10, 15, 20, 25, and 30 were exposed for 12 h in the absence or presence of REAC in six-well plates (6 × 10^3^ cells per well). Cell viability was determined by the trypan blue dye exclusion test (Life Technologies). Both attached and floating cells were harvested and counted by using countess automated cell counter.

Adipogenesis, osteogenesis, and vasculogenesis in culture {#Sec10}
---------------------------------------------------------

To test cell capability to differentiate toward mesenchymal phenotypes, hADSCs at passages 5 and 30, exposed or not to REAC for 12 h, were committed toward adipogenic, osteogenic, and vascular phenotypes. To induce adipogenic differentiation, 10 × 10^3^ cells/cm^2^ were cultured in an adipogenesis induction medium (Millipore) composed by DMEM-low glucose, supplemented with 10 % FBS, 0.5 mM isobutyl-methylxanthine, 200 μM indomethacin, 1 μM dexamethasone, and 10 μg/mL insulin in a 24-well microplate, replacing the medium every 2--3 days. At day 7 and 10 of differentiation, total RNA was extracted and the expression of the two adipogenic markers, adipocyte Protein 2 (aP2) and peroxisome proliferator-activated receptor γ (PPARγ), was evaluated by real-time PCR. After 2--3 weeks of culture, the cells were fixed in 10 % formalin and stained with fresh oil red-O solution. To induce osteogenic differentiation, 10 × 10^3^ cells/cm^2^ were plated in a 24-well microplate in DMEM-low glucose supplemented with 10 % FBS, 10 mM β-glycerophosphate, 0.2 mM ascorbic acid, and 10 nM dexamethasone (Mesenchymal Stem Cell Osteogenesis Kit, Millipore), and cultured for 3--4 weeks, replacing the medium every 2--3 days. To demonstrate osteogenic differentiation, the cultures were fixed and stained with Alizarin Red solution, and total RNA was extracted to evaluate specific osteogenic differentiation related genes, as Runt-related transcription factor 2 (RUNX-2) and bone sialoprotein (BSP). Concerning angiogenesis, as previously shown the expression of vasculogenic genes, including vascular endothelial growth factor (VEGF), and von Willebrand factor (vWF) genes can be remarkably enhanced following the exposure of hADSCs to a mixture of natural molecules including hyaluronan (H), butyric (B), and retinoic acids (R) (Bianchi et al. [@CR4]; Cavallari et al. [@CR7]). Here, we use a 24--72-h exposure to a mixture containing H (2 mg/mL), B (5 mM), and R (1 μM) to induce the expression of the vasculogenic gene VEGF, and the vascular marker vWF factor. Analysis of capillary-like tube formation was performed using Cultrex® Basement Membrane Extract (BME, Thema). Capillary-like structures were observed after 12--24 h at regular time intervals, and photographed using an inverted optical microscope equipped with a digital sight camera (Nikon).

Gene expression {#Sec11}
---------------

Total RNA was isolated from hADSCs exposed or not to TO-RGN for 4, 8, or 12 h, using Trizol reagent according to the manufacturer\'s instruction (Life Technologies). Total RNA was also isolated from control and REAC-treated hADSCs (time of exposure 12 h) at passages 5° and 30° committed toward adipogenic (at days 7 and 10 of culture), osteogenic (at day 7 of culture) and vascular (at day 7 of culture) phenotypes. Total RNA was dissolved in RNAase-free water, and for RT-PCR, cDNA was synthesized in a 50-μL reaction volume with 1 μg of total RNA and MuMLV reverse transcriptase (RT) according to the manufacturer\'s instruction (Invitrogen). Quantitative real-time PCR was performed using an iCycler Thermal Cycler (Bio-Rad). Two microliters of cDNA were amplified in 50-μL reactions using Platinum Supermix UDG (Invitrogen), 200 nM of each primer, 10 nM fluorescein (BioRad), and Sybr Green. After an initial denaturation step at 94 °C for 10 min, temperature cycling was initiated. Each cycle consisted of 94 °C for 15 s, 55--59 °C for 30 s, and 60 °C for 30 s, the fluorescence being read at the end of this step. To evaluate the quality of product of real-time PCR assays, melting curve analysis was performed after each assay. Relative expression was determined using the "delta-CT method" with hypoxanthine phosphoribosyltransferase 1 (*HPRT1*) as a reference gene. The mRNA levels of control and TO-RGN exposed hADSCs were expressed as fold of change (2 −∆∆Ct), relative to the mRNA levels of the enzyme evaluated in hADSCs at passage 5 when cells reached 80 % confluence before starting TO-RGN treatment (time 0).

Specific primers for p16, p19, p21, p53, and HPRT1 used in this study were from Invitrogen and previously described (Maioli et al. [@CR13]; Bea et al. [@CR3]; Isenmann et al. [@CR10]; Vandesompele et al. [@CR29]; Maioli et al. [@CR15]). Specific primers used for adipogenic commitment were: aP2 forward 5′-AGACATTCTACGGGCAGCAC-3′ and reverse 5′-TCATTTTCCCACTCCAGCCC-3′, and PPARγ forward 5′-GCAAACCCCTATTCCATGCTG-3′ and reverse GCAGGCTCCACTTTGATTGC.

Specific primers for osteogenic commitment, as core binding factor alpha 1 (CBFA1/RUNX-2), and BSP, were previously described (Polini et al. [@CR21]).

Specific primers for angiogenesis as VEGF were previously described (Ventura et al. [@CR30]) while primers for the vascular marker vWF were: forward 5′-GCCTGTGGGAGCAGTGCCAG-3′ and reverse 5′-GGGCGTACTCCAGGAGGGCA-3′.

Data analysis {#Sec12}
-------------

The statistical analysis of the data was performed by using the Statistical Package for Social Science, version 13. For this study, nonparametric statistical tests were used: Friedman and Wilcoxon-signed rank test. The first was used to detect differences in treatments across multiple test attempts; the second was used to evaluate, in the same group, the differences (delta CT) between the data collected over a period of observation related to the treated and nontreated cells. Test, and all results *P* \< 0.05 have been considered statistically significant.

Results {#Sec13}
=======

TO-RGN treatment remarkably influenced cell viability, as shown by its ability to significantly enhance the number of vital cells as compared to untreated controls (Fig. [1](#Fig1){ref-type="fig"}). Figure [2](#Fig2){ref-type="fig"} (panels A--F) represents SA-β-Gal staining in hADSCs cultured in the absence or presence of TO-RGN throughout an observation period of 90 days. It is evident that the number of SA-β-Gal-stained cells (blue) was already significantly reduced at passage 5 in TO-RGN-treated hADSCs. This behavior became more evident with the passage of time in culture, with a progressive increment in the difference of positively SA-β-Gal-stained cells between REAC exposed and unexposed cells (Fig. [2](#Fig2){ref-type="fig"}, panels A--F). Moreover, in the last passages not only the number of SA-β-Gal positive cells, but also the intensity of the SA-β-Gal staining was remarkably reduced following TO-RGN exposure. Separate analysis of cellular morphology revealed that unlike control cells, which developed an ailing morphology in the last passages, TO-RGN-exposed cells still exhibited their classical fibroblast-like morphology, even at passages 25 and 30. In particular, length to width ratio was higher in REAC-treated cells, ranging between 8.078 ± 0.6 and 5.043 ± 0.55 (mean ± SD from ten separate REAC-exposed cell cultures at passages 25 and 30, respectively), as compared to untreated cells, ranging between 5.025 ± 0.35 and 3.993 ± 0.33 (mean ± SD from ten separate untreated control cell cultures at passages 25 and 30, respectively).Fig. 1TO-RGN exposure enhances hADSC viability. After plating (6 × 10^3^ cells/well), cells were left untreated or treated with TO-RGN for 12 h and counted to estimate cell growth. The number of vital cells assed by trypan blue dye exclusion was significantly higher in REAC-exposed samples than in untreated controls. (*Asterisk*) significantly different from untreated cells (mean ± SD, *n* = 4) (*P* \< 0.05)Fig. 2REAC TO-RGN counteracts senescence-associated β-galactosidase activity. hADSCs at passages 5 (*panels A*), 15 (*panels B*), 20 (*panels C*), 25 (*panels D*), and 30 (*panels E*) were plated in six-well plates (3 × 10^3^ cells per well). After overnight culture for attachment, cells were cultured in the absence or presence of REAC for 12 h. Then, hADSCs were processed for SA-β-Gal assessment and photographed under a microscope at 100× magnification. SA-β-Gal activity was measured after culturing for 12 h with (*blue line*) or without TO-RGN (*red line*) treatment (*panel F*). The number of positive (blue staining) and negative cells was counted in five random fields under the microscope (at 200× magnification and bright field illumination), and the percentage of SA-β-Gal-positive cells was calculated as the number of positive cells divided by total number of counted cells. (*Asterik*) significantly different from the untreated cells (mean ± SD, *n* = 3) (*P* \< 0.05)

Figures [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, and [6](#Fig6){ref-type="fig"} show respectively the gene expression of p16INK4, ARF, p53 and p21 in hADSCs at passages 5, 10, 15, 20, 25, and 30 treated, or not, with TO-RGN for 4, 8, or 12 h. The expression of p16, ARF p53, and p21 increased throughout the investigated culturing passages (Figs. [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, and [6](#Fig6){ref-type="fig"}) in control hADSCs, while it was significantly less detectable in TO-RGN-exposed cells. Moreover, this effect of TO-RGN was particularly evident at passages 25 and 30. hADSCs at passages 5 and 30 treated with TO-RGN exhibited also a higher differentiation capability toward adipogenic, osteogenic, and vasculogenic lineages, as compared to control cells (Fig. [7](#Fig7){ref-type="fig"}, panels a--c). Adipogenic differentiation showed multiple adipocytic multivacuolar cells, the size increasing with the time of induction (Fig. [7](#Fig7){ref-type="fig"}, panels a). Moreover, hADSCs at passages 30 exposed to TO-RGN also expressed higher levels of the adipogenic-associated genes, aP2 and PPARγ, as compared to control cells (Fig. [7](#Fig7){ref-type="fig"}, panels a). Osteogenic differentiation was revealed as early as the first week of induction by morphological changes and, at the end of the induction period, by the formation of mineralized matrix and calcium deposits as demonstrated by Alizarin Red staining (Fig. [7](#Fig7){ref-type="fig"}, panels b). Gene expression analysis of osteogenic-associated genes, RUNX2 and BSP revealed higher expression levels of both factors in TO-RGN-treated hADSCs, as compared to control cells (Fig. [7](#Fig7){ref-type="fig"}, panels b). Vasculogenic differentiation was assessed in control or TO-RGN-treated hADSCs cultured for 24 h in semisolid medium, at passages 5 and 30 (Fig. [7](#Fig7){ref-type="fig"}, panels c). The TO-RGN treatment increased both the number of capillary-like tubes and their branching assembly, as compared with unexposed controls (Fig. [7](#Fig7){ref-type="fig"}, panels c). The higher vasculogenic differentiation capability of TO-RGN-treated hADSCs was also inferred by their enhanced expression of the vasculogenic gene VEGF and of the vascular specific gene *vWF*, with respect to untreated cells (Fig. [7](#Fig7){ref-type="fig"}, panels c).Fig. 3Effect of REAC TO-RGN on p16INK4a gene expression. hADSCs at passages 5, 10, 15, 20, 25, and 30, reaching 80 % confluence, were exposed for 4, 8, or 12 h in the absence or presence of REAC. The amount of p16INK4a mRNA from control (*white bars*) and TO-RGN treated (*blue bars*) cells was normalized to HPRT1 and was plotted as fold change relative to the mRNA expression at passage 5 (time 0), defined as 1. (*Asterisk*) significantly different from the untreated cells (mean ± S.E.; *n* = 6) (*P* \< 0.05)Fig. 4Effect of REAC TO-RGN on ARF gene expression. hADSCs at passages 5, 10, 15, 20, 25, and 30, reaching 80 % confluence, were exposed for 4, 8, or 12 h in the absence or presence of REAC. The amount of ARF mRNA from control (*white bars*) and TO-RGN-treated (*red bars*) cells was normalized to HPRT1 and was plotted as fold change relative to the mRNA expression at passage 5 (time 0), defined as 1. (*Asterisk*) significantly different from the untreated cells (mean ± S.E.; *n* = 6) (*P* \< 0.05)Fig. 5Effect of REAC TO-RGN on p53 gene expression. hADSCs at passages 5, 10, 15, 20, 25, and 30, reaching 80 % confluence, were exposed for 4, 8, or 12 h in the absence or presence of REAC. The amount of p53 mRNA from control (*white bars*) and TO-RGN-treated (*purple bars*) cells was normalized to HPRT1 and was plotted as fold change relative to the mRNA expression at passage 5 (time 0), defined as 1. (*Asterisk*) significantly different from the untreated cells (mean ± S.E.; *n* = 6) (*P* \< 0.05)Fig. 6Effect of REAC TO-RGN on p21 gene expression. hADSCs at passages 5, 10, 15, 20, 25, and 30, reaching 80 % confluence, were exposed for 4, 8, or 12 h in the absence or presence of REAC. The amount of p21 mRNA from control (*white bars*) and TO-RGN-treated (*green bars*) cells was normalized to HPRT1 and was plotted as fold change relative to the mRNA expression at passage 5 (time 0), defined as 1. (*Asterisk*) significantly different from the untreated cells (mean ± S.E.; *n* = 6) (*P* \< 0.05)Fig. 7Effect of REAC on multi-lineage differentiation and gene expression patterning in hADSCs cultured at different passages in the absence or presence of REAC. At passages 5, or 30, hADSCs were treated for 12 h in the absence or presence of REAC, and processed as described under "Material and methods" for: **a** adipogenic differentiation, revealed by Oil Red-O staining for neutral lipids (100× magnification), and by the gene expression of aP2 and PPARγ; **b** osteogenic differentiation, evidenced by the formation of mineralized matrix, as shown by Alizarin Red staining (100× magnification), and by the gene expression of BSP and RUNX2. **c** Vasculogenic differentiation was assessed by capillary tube-like formation in semisolid medium after 24 h of treatment in the absence or presence of REAC (100×, original magnification), and by the gene expression analysis of VEGF and vWF. (*White bars*) untreated controls; (*black bars*) REAC-treated cells. Immunohistochemistry is representative of four separate experiments. For gene expression analyses, total RNA was extracted after 7 days in culture. (*Asterisk*) Significantly different from untreated control cells (mean ± S.E.; *n* = 6)

Discussion {#Sec14}
==========

It has been demonstrated that the regenerative capability of stem cells isolated from elder patients is lower as compared to younger subjects (Lapasset et al. [@CR11]). This age-related alteration, together with a reduced self-renewal potential of adult stem cells, can also be observed during long-term culture in vitro (Chambers and Goodell [@CR8]). Therefore, identifying a strategy that could revert the molecular cues controlling stem cell senescence in vitro may represent an important progress for future cell therapy development. Indeed, advances in the perspective of a regenerative medicine were recently obtained by reversing the age-altered physiology of the stem cells by the aid of viral vectors (Sawada et al. [@CR27]). Alternatively, (stem) cell rejuvenation has been shown after culturing in a hypoxic environment (Barros et al. [@CR2]; Leontieva et al. [@CR12]; Malladi et al. [@CR16]), a condition influencing cell proliferation and fate (Malladi et al. [@CR16]; Mohyeldin et al. [@CR18]), although hypoxia was also found to induce apoptosis in bone marrow-derived hMSCs (Zhu et al. [@CR33]).

In the present work, we analyzed the effect of TO-RGN treatment on hADSC senescence in vitro, and demonstrated that this physical treatment, without the aid of viral vectors, was able to counteract biochemical and morphological changes occurring in stem cells during aging. Such a conclusion could be inferred from a number of interrelated observations, including (1) the effectiveness of TO-RGN to decrease both the number of SA-β-Gal-positive cells and their staining intensity, (2) the ability of TO-RGN-treated cells to retain the typical fibroblast-like morphology of hADSCs, with respect to the enlarged shape acquired by unexposed cells through prolonged culturing, (3) the remarkable preservation of the multilineage differentiating potential observed in TO-RGN exposed hADSCs that even at late passages retained their adipogenic, osteogenic, and vasculogenic potential, as compared with the multipotency decline found in aged, unexposed cells.

It is now evident that senescence is also regulated by specific mediator genes, accumulating during the cell life span, including p16INK4, ARF, p53, and p21CIP1. In particular, p16INK4 and ARF inhibit the activity of cyclin-dependent kinase 4 and 6, essential for the G1 progression through the cell cycle, while p53 regulates the expression of p21 CIP1, which inhibits cyclin-dependent kinase2, a regulator of the S phase progression (Zou et al. [@CR35]).

Our observation that TO-RGN exposure was also effective in counteracting the progressive upregulation of these genes occurring throughout multiple passages in culture supports future clinical application of REAC technology as a potential tool for blunting age-related degenerative diseases.

Further studies are in progress to investigate whether the TO-RGN treatment may also interact with the multifaceted signal patterning through which hypoxia determines the cell state and inhibits geroconversion (Leontieva et al. [@CR12]).
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